Adolor inks $72M deal to in-license Lilly OBD drug

Adolor has plunked down $2 million upfront and committed to pay $70 million more in milestones for Eli Lilly's OpRA III, a clinical stage product being developed for opioid bowel dysfunction. Adolor says it will soon launch a new trial for the drug, which will be developed alongside ADL7445 as part of its OBD Program. From now on, OpRA III will be identified as ADL5945.

"OpRA III has a unique profile with the potential to address the gastrointestinal disorders associated with the use of opioid analgesics," said Michael R. Dougherty, president and CEO of Adolor. "Adolor has a wealth of experience in this therapeutic area and the addition of OpRA III to our OBD portfolio provides us with another clinical-stage compound with which we can potentially address a large and underserved market."

Lilly has completed both a Phase I single, escalating dose placebo-controlled safety study and a Phase I multiple, escalating dose placebo-controlled safety study in healthy volunteers for OpRA III.

- check out the release for more info

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Canadian biotech AbCellera has nabbed a meaty $105 million series B funding round as it looks to boost its antibody work and seek out new potential me